| アブストラクト | BACKGROUND: Ocrelizumab, an anti-CD20 monoclonal antibody, has proven effective in reducing relapses and disease progression in multiple sclerosis. While neutropenia is a known adverse effect of anti-CD20 therapies, data on the clinical severity, recurrence risk, and management of ocrelizumab-induced neutropenia (OIN) remain limited. OBJECTIVES: Describe clinical severity, recurrence risk and management of OIN. METHODS: We performed a retrospective observational study based on OIN reports from the French Pharmacovigilance Database. A questionnaire was sent to clinicians who had reported cases. Patients with moderate or severe neutropenia (< 1.0 G/L) were included. RESULTS: Thirty-four cases of OIN were analysed. Neutropenia was mostly late-onset (>4 weeks post-cycle, 94.1 %) and occurred mainly after the first (32.4 %), second or third cycle (26.5 %). Most patients (55.9 %) were asymptomatic, 32.4 % developed infections and 11.8 % presented agranulocytosis symptoms. Ocrelizumab was reintroduced in 15 patients, with recurrence in 4 cases (26.6 %). Two cases of recurrent neutropenia were reported after switching to ofatumumab. CONCLUSION: OIN is an intermittent adverse event, often discovered incidentally and generally not severe. Most cases are likely to go undetected as asymptomatic. With a recurrence rate of 25 %, rechallenging with ocrelizumab should be considered based on MS condition of the patient and available alternative treatment. |
|---|
| ジャーナル名 | Multiple sclerosis and related disorders |
|---|
| Pubmed追加日 | 2025/9/28 |
|---|
| 投稿者 | Brochard, Vincent; Le Vavasseur, Benjamin; Pinel, Sylvine; Bihan, Kevin; Bourneau Martin, Delphine; Boudot de la Motte, Marine; Chaugne, Emeline; Deschamps, Romain; Bensa, Caroline; Papeix, Caroline |
|---|
| 組織名 | Department of Neurology, Hopital Fondation Adolphe de Rothschild, Paris, France.;Electronic address: vbrochard@for.paris.;Department Interspeciality, Hopital Fondation Adolphe de Rothschild, Paris,;France.;Centre de Pharmacovigilance de Paris Saint-Louis, Assistance Publique-Hopitaux de;Paris, Paris, France.;Pharmacology Department, AP-HP, GHU Sorbonne University, Regional;Pharmacovigilance Centre Pitie-Saint Antoine, Paris, France.;Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre;Hospitalo-Universitaire d'Angers, 4 rue Larrey 49100 Angers, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41014780/ |
|---|
